Zusammenfassung
Die Harninkontinenz nimmt aufgrund der Verschiebung der Bevölkerungsstrukturen hin zu höherem Lebensalter stetig zu. Sie stellt aber nicht nur gesellschaftlich, sondern auch ökonomisch und medizinisch ein steigendes und zu bewältigendes Problem dar.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Armstrong RB, Luber KM, Peters KM (2005) Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder. Int Urol Nephrol 37: 247–252
Blue DR, Daniels DV, Gever JR, Jett MF, O’Yang C, Tang HM, Williams TJ,Ford AP (2004) Pharmacological characteristics of Ro 115-1240, a selective alpha1A/1L-adrenoceptor partial agonist: a potential therapy for stress urinary incontinence. BJU Int 93: 162–170
Cartwright R, Cardozo L (2007) Transdermal oxybutynin: sticking to the facts. Eur Urol 51: 907–914
Chapple CR, Patroneva A, Raines SR (2006) Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004). Eur Urol 49: 879–886
Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M,Ridder A, YM-905 Study Group (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93: 303–310
De Ridder D, Baert L (2000) Vanilloids and the overactive bladder. BJU Int 86: 172–180
Dmochowski RR, Appell RA (2000) Advancements in pharmacologic management of the overactive bladder. Urology 56: 41–49
Fuller RW, Hemrick-Luecke SK, Snoddy HD (1994) Effects of duloxetine,an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice. J Pharmacol Exp Ther 269: 132–136
Ghoniem GM, Van Leeuwen JS, Elser DM, Freeman RM, Zhao YD, Yalcin I, Bump RC; Duloxetine/Pelvic Floor Muscle Training Clinical Trial Group (2005) A randomized controlled trial of duloxetine alone,pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 173: 1647–1653
Haab F, Corcos J, Siami P, Glavind K, Dwyer P, Steel M, Kawakami F, Lheritier K, Steers WD (2006) Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int 98: 1025–1032
Hills CJ, Winter SA, Balfour JA (1998) Tolterodine. Drugs 55: 813–820
Jost WH, Marsalek P, Michel MC (2005) Pharmacotherapy of stress incontinence. Dtsch Med Wochenschr 130: 2337–2342
Michel MC, Vrydag W (2006) Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 147: S88–119
Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC; Duloxetine UI Study Group (2004) Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int 93: 311–318
Robinson D, Cardozo LD (2003) The role of estrogens in female lower urinary tract dysfunction. Urology 62: 45–51
Schurch B (2006) Botulinum toxin for the management of bladder dysfunction. Drugs 66: 1301–1318
Stohrer M, Murtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele JJ; Propiverine Investigator Group (2007) Propiverine compared to oxybutynin in neurogenic detrusor overactivity – results of a randomized, double-blind, multicenter clinical study. Eur Urol 51: 235–242
Thor KB, Katofiasc MA (1995) Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 274: 1014–1024
Truss MC, Stief CG, Uckert S, Becker AJ, Wefer J, Schultheiss D, Jonas U (2001) Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol 19:344–350
Zinner NR (2005) Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder. Expert Opin Pharmacother 6: 1409–1420
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Hegele, A. (2009). Pharmakologie der Drang- und Belastungsharninkontinenz. In: Inkontinenz- und Deszensuschirurgie der Frau. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-79938-2_8
Download citation
DOI: https://doi.org/10.1007/978-3-540-79938-2_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-35033-7
Online ISBN: 978-3-540-79938-2
eBook Packages: Medicine (German Language)